title: Randomized clinical trials in advanced and metastatic colorectal carcinoma.
abstract: The treatment of advanced colorectal cancer has long been a dilemma for clinicians. After many years of therapy limited to 5-fluorouracil (5-FU)-based chemotherapy, a number of new discoveries have significantly advanced this field in the last decade. The advent of irinotecan has given us hope for a second line chemotherapeutic agent and a possible new combination for first line chemotherapy.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. dangelim@mskcc.org
authors.forename: Michael I
authors.initials: MI
authors.lastname: Dangelica
authors.forename: Margo C
authors.initials: MC
authors.lastname: Shoup
authors.forename: Aviram
authors.initials: A
authors.lastname: Nissan
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019317:Evidence-Based Medicine; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008495:Medical Oncology; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil